128 related articles for article (PubMed ID: 33875290)
1. Shared and oppositely regulated transcriptomic signatures in Huntington's disease and brain ischemia confirm known and unveil novel potential neuroprotective genes.
Yildirim F; Foddis M; Blumenau S; Müller S; Kajetan B; Holtgrewe M; Kola V; Beule D; Sassi C
Neurobiol Aging; 2021 Aug; 104():122.e1-122.e17. PubMed ID: 33875290
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
Elife; 2021 Apr; 10():. PubMed ID: 33871358
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide Analysis of RARβ Transcriptional Targets in Mouse Striatum Links Retinoic Acid Signaling with Huntington's Disease and Other Neurodegenerative Disorders.
Niewiadomska-Cimicka A; Krzyżosiak A; Ye T; Podleśny-Drabiniok A; Dembélé D; Dollé P; Krężel W
Mol Neurobiol; 2017 Jul; 54(5):3859-3878. PubMed ID: 27405468
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional correlates of the pathological phenotype in a Huntington's disease mouse model.
Gallardo-Orihuela A; Hervás-Corpión I; Hierro-Bujalance C; Sanchez-Sotano D; Jiménez-Gómez G; Mora-López F; Campos-Caro A; Garcia-Alloza M; Valor LM
Sci Rep; 2019 Dec; 9(1):18696. PubMed ID: 31822756
[TBL] [Abstract][Full Text] [Related]
5. Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice.
MacGibbon GA; Hamilton LC; Crocker SF; Costain WJ; Murphy KM; Robertson HA; Denovan-Wright EM
J Neurosci Res; 2002 Feb; 67(3):372-8. PubMed ID: 11813242
[TBL] [Abstract][Full Text] [Related]
6. Reduced Expression of Foxp1 as a Contributing Factor in Huntington's Disease.
Louis Sam Titus ASC; Yusuff T; Cassar M; Thomas E; Kretzschmar D; D'Mello SR
J Neurosci; 2017 Jul; 37(27):6575-6587. PubMed ID: 28550168
[TBL] [Abstract][Full Text] [Related]
7. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
[TBL] [Abstract][Full Text] [Related]
8. Degeneration of ipRGCs in Mouse Models of Huntington's Disease Disrupts Non-Image-Forming Behaviors Before Motor Impairment.
Lin MS; Liao PY; Chen HM; Chang CP; Chen SK; Chern Y
J Neurosci; 2019 Feb; 39(8):1505-1524. PubMed ID: 30587542
[TBL] [Abstract][Full Text] [Related]
9. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation.
Zourlidou A; Gidalevitz T; Kristiansen M; Landles C; Woodman B; Wells DJ; Latchman DS; de Belleroche J; Tabrizi SJ; Morimoto RI; Bates GP
Hum Mol Genet; 2007 May; 16(9):1078-90. PubMed ID: 17360721
[TBL] [Abstract][Full Text] [Related]
10. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration.
Strand AD; Baquet ZC; Aragaki AK; Holmans P; Yang L; Cleren C; Beal MF; Jones L; Kooperberg C; Olson JM; Jones KR
J Neurosci; 2007 Oct; 27(43):11758-68. PubMed ID: 17959817
[TBL] [Abstract][Full Text] [Related]
11. Activation of Elk-1 participates as a neuroprotective compensatory mechanism in models of Huntington's disease.
Anglada-Huguet M; Giralt A; Perez-Navarro E; Alberch J; Xifró X
J Neurochem; 2012 May; 121(4):639-48. PubMed ID: 22372926
[TBL] [Abstract][Full Text] [Related]
12. CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease.
Boussicault L; Alves S; Lamazière A; Planques A; Heck N; Moumné L; Despres G; Bolte S; Hu A; Pagès C; Galvan L; Piguet F; Aubourg P; Cartier N; Caboche J; Betuing S
Brain; 2016 Mar; 139(Pt 3):953-70. PubMed ID: 26912634
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNAs in Huntington's disease neurodegeneration.
Johnson R
Neurobiol Dis; 2012 May; 46(2):245-54. PubMed ID: 22202438
[TBL] [Abstract][Full Text] [Related]
14. Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease.
Smith GA; Rocha EM; McLean JR; Hayes MA; Izen SC; Isacson O; Hallett PJ
Hum Mol Genet; 2014 Sep; 23(17):4510-27. PubMed ID: 24728190
[TBL] [Abstract][Full Text] [Related]
15. Consistent neurodegeneration and its association with clinical progression in Huntington's disease: a coordinate-based meta-analysis.
Dogan I; Eickhoff SB; Schulz JB; Shah NJ; Laird AR; Fox PT; Reetz K
Neurodegener Dis; 2013; 12(1):23-35. PubMed ID: 22922585
[TBL] [Abstract][Full Text] [Related]
16. Striatal pre-enkephalin overexpression improves Huntington's disease symptoms in the R6/2 mouse model of Huntington's disease.
Bissonnette S; Vaillancourt M; Hébert SS; Drolet G; Samadi P
PLoS One; 2013; 8(9):e75099. PubMed ID: 24040390
[TBL] [Abstract][Full Text] [Related]
17. Striatal atrophy and dendritic alterations in a knock-in mouse model of Huntington's disease.
Lerner RP; Trejo Martinez Ldel C; Zhu C; Chesselet MF; Hickey MA
Brain Res Bull; 2012 Apr; 87(6):571-8. PubMed ID: 22326483
[TBL] [Abstract][Full Text] [Related]
18. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.
Giampà C; Laurenti D; Anzilotti S; Bernardi G; Menniti FS; Fusco FR
PLoS One; 2010 Oct; 5(10):e13417. PubMed ID: 20976216
[TBL] [Abstract][Full Text] [Related]
20. AAV5-miHTT-mediated huntingtin lowering improves brain health in a Huntington's disease mouse model.
Thomson SB; Stam A; Brouwers C; Fodale V; Bresciani A; Vermeulen M; Mostafavi S; Petkau TL; Hill A; Yung A; Russell-Schulz B; Kozlowski P; MacKay A; Ma D; Beg MF; Evers MM; Vallès A; Leavitt BR
Brain; 2023 Jun; 146(6):2298-2315. PubMed ID: 36508327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
